Research Findings Published peer-reviewed laboratory literature characterizes Ipamorelin as a selective GHS-R1a agonist that produces pulsatile GH release in rodent and swine in-vivo models without measurable elevation of stress-hormone or gonadotropin axes at preclinical doses
a Japanese single-center, retrospective-study
Comparison with the Effects of GHRH, TRH and hCRH, Peptides, Volume 18, Issue 6, 1997, Pages 885-891, ISSN 0196-9781, Chihara K, Shimatsu A, Hizuka N, Tanaka T, Seino Y, Katofor Y
This double-blind placebo-controlled study was performed between May 2011 and October 2016 at Nova Southeastern University (Fort Lauderdale, FL, USA) at three locations: The Mailman Segal Center (informed consent and behavioral assessments: visits 1, 3, 4, 5, 6, and 7), Nova Southeastern University Clinic (pediatric visits 2 and 8, including blood sampling), and the blood samples were quantified at the College of Pharmacy
Researchers comparing supplier formats can review the CJC-1295 + Ipamorelin peptide blend product page , the CJC-1295 product page , and the Ipamorelin product page
Clinical research shows it can raise blood glutathione levels by up to 3035%
